Sarepta Therapeutics, Inc. (SRPT): debt financing — Sarepta exchanges $700M convertible notes for $602M new 4.875% notes due 2030 plus stock and cash

Sarepta Therapeutics, Inc.

Exchanged $700M of 1.25% Convertible Notes due 2027 for $602M of 4.875% Convertible Notes due 2030, 5.85M common shares, and ~$123.3M cash.
New notes mature Sept 1, 2030; initial conversion price ~$60.00/share (191.5% premium over $20.58 close on Aug 20, 2025).
Concurrent private placement of 1,106,806 shares to J. Wood Capital at $18.07 per share.
New notes bear 4.875% cash interest, payable semiannually; callable from Sept 6, 2028 if stock price ≥ 130% of conversion price.
Holders may convert upon stock price triggers (≥130% of conversion price for 20 of 30 days) or specified corporate events.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Sarepta Therapeutics, Inc. incurred convertible notes of $602.0 million in aggregate principal amount with U.S. Bank Trust Company, National Association at 4.875% maturing September 1, 2030.

Instrument: convertible notes
Principal: $602.0 million in aggregate principal amount
Counterparty: U.S. Bank Trust Company, National Association
Rate: 4.875%
Maturity: September 1, 2030
Event: incurrence

Exact text from the filing

party thereto agreed to exchange with the Company $700.0 million in aggregate principal amount of Existing Convertible Notes held by them for consideration consisting of (i) $602.0 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030 (the “New Convertible Notes”), (ii) an aggregate of 5,851,693 shares of the Company’s common stock, par

View on SEC.gov

10 debt financings filed in the last 30 days. Browse all debt financings →

Sarepta Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-192794

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.